Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ViewPoint Therapeutics

ViewPoint Therapeutics
2014 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series B LATEST DEAL TYPE
$35M LATEST DEAL AMOUNT
12 INVESTORS
Description

Developer of crystallin stabilizers intended to prevent and treat cataracts and presbyopia. The company's crystallin stabilizers include VP1-001, which is a small molecule that is active in preclinical models of age-related cataracts via a target-based screening and optimization effort, enabling users to get drugs to prevent or reverse protein misfolding, which is implicated in numerous common disorders of aging including cataracts, presbyopia, and neurodegenerative diseases.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • 290 Utah Avenue
  • Suite 300
  • South San Francisco, CA 94080
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore ViewPoint Therapeutics’s full profile, request a free trial.

ViewPoint Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 05-Mar-2018 $35M 0000 0000 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 02-May-2016 00.000 00.000 000.00 Completed Pre-Clinical Trials
2. Grant 01-Apr-2016 $222K Completed Pre-Clinical Trials
1. Accelerator/Incubator 06-Oct-2014 Completed Pre-Clinical Trials
To view this company’s complete deal history including valuation and funding, request access »

ViewPoint Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

ViewPoint Therapeutics Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lysosomal Therapeutics Venture Capital-Backed Cambridge, MA 00 000.00 0&0
000000000 Formerly VC-backed Copenhagen, Denmark 00 00000 00000000 00000
00000000 000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
0000 000000000000 Venture Capital-Backed Cambridge, United Kingdom 0000 00000000000 0000
0000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
To view this company’s complete list of competitors, request access »

ViewPoint Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Novo Holdings Corporate Venture Capital Minority 000 0000 000000 0
The Rise Fund Impact Investing Minority 000 0000 000000 0
Asset Management Ventures Venture Capital Minority 000 0000 000000 0
BVF Partners Hedge Fund Minority 000 0000 000000 0
Edward Hurwitz Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

ViewPoint Therapeutics Executive Team (4)

Name Title Board
Seat
Contact
Info
Leah Makley Ph.D Co-Founder, Chief Executive Officer, Board Member & President
Jason Gestwicki Ph.D Co-Founder, Director & Key Advisor
Edward Hurwitz Co-Founder & Chairman

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »

ViewPoint Therapeutics Board Members (6)

Name Representing Role Since Contact
Info
Edward Hurwitz Self Co-Founder & Chairman 000 0000
Emmett Cunningham Ph.D ViewPoint Therapeutics Board Member 000 0000
Heath Lukatch Ph.D Novo Holdings Board Member 000 0000
Peter Moldt Ph.D Novo Holdings Board Member 000 0000

2 Former Board Members

You’re viewing 4 of 6 board members. Get the full list »